 Mark Abzug
Concepts (407)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Enterovirus Infections | 21 | 2019 | 148 | 3.580 |
Why?
| | HIV Infections | 26 | 2022 | 2487 | 2.230 |
Why?
| | Antiretroviral Therapy, Highly Active | 9 | 2017 | 282 | 2.060 |
Why?
| | Pneumococcal Vaccines | 5 | 2021 | 134 | 2.000 |
Why?
| | Pregnancy Complications, Infectious | 14 | 2015 | 265 | 1.820 |
Why?
| | Antiviral Agents | 11 | 2021 | 639 | 1.760 |
Why?
| | Enterovirus | 9 | 2019 | 70 | 1.500 |
Why?
| | Hematopoietic Stem Cell Transplantation | 4 | 2021 | 575 | 1.270 |
Why?
| | Immunologic Memory | 3 | 2013 | 311 | 1.200 |
Why?
| | Pneumococcal Infections | 3 | 2013 | 96 | 1.150 |
Why?
| | Immunization, Secondary | 4 | 2021 | 76 | 1.140 |
Why?
| | Oxadiazoles | 4 | 2015 | 32 | 1.050 |
Why?
| | Paralysis | 4 | 2018 | 66 | 0.920 |
Why?
| | Child | 52 | 2022 | 17711 | 0.820 |
Why?
| | Sinusitis | 7 | 2013 | 157 | 0.760 |
Why?
| | Vaccination | 4 | 2017 | 962 | 0.750 |
Why?
| | Mucositis | 1 | 2018 | 18 | 0.730 |
Why?
| | Triazoles | 2 | 2018 | 144 | 0.730 |
Why?
| | Meningoencephalitis | 1 | 2017 | 25 | 0.700 |
Why?
| | Influenza, Human | 5 | 2015 | 462 | 0.700 |
Why?
| | Antibodies, Bacterial | 4 | 2013 | 137 | 0.680 |
Why?
| | Myelitis | 4 | 2019 | 94 | 0.670 |
Why?
| | Anti-Retroviral Agents | 7 | 2018 | 196 | 0.670 |
Why?
| | Theilovirus | 4 | 2000 | 6 | 0.660 |
Why?
| | Graft vs Host Disease | 1 | 2018 | 229 | 0.630 |
Why?
| | Encephalitis | 1 | 2017 | 123 | 0.620 |
Why?
| | Influenza A Virus, H1N1 Subtype | 3 | 2015 | 136 | 0.620 |
Why?
| | Neonatal Sepsis | 1 | 2015 | 3 | 0.600 |
Why?
| | Encephalomyelitis, Acute Disseminated | 1 | 2015 | 11 | 0.600 |
Why?
| | Central Nervous System Viral Diseases | 4 | 2019 | 62 | 0.600 |
Why?
| | Influenza Vaccines | 3 | 2015 | 409 | 0.580 |
Why?
| | Herpes Simplex | 4 | 2017 | 97 | 0.580 |
Why?
| | Immunocompromised Host | 5 | 2021 | 218 | 0.570 |
Why?
| | Disease Outbreaks | 6 | 2019 | 284 | 0.570 |
Why?
| | Neuromyelitis Optica | 1 | 2015 | 89 | 0.560 |
Why?
| | Placenta | 6 | 2000 | 568 | 0.540 |
Why?
| | Infant, Newborn | 25 | 2018 | 5080 | 0.520 |
Why?
| | CD4 Lymphocyte Count | 8 | 2022 | 299 | 0.510 |
Why?
| | Neuromuscular Diseases | 3 | 2019 | 99 | 0.510 |
Why?
| | Humans | 85 | 2022 | 113846 | 0.510 |
Why?
| | Measles Vaccine | 1 | 2012 | 19 | 0.490 |
Why?
| | Infant | 26 | 2020 | 8090 | 0.490 |
Why?
| | Adolescent | 35 | 2022 | 18736 | 0.490 |
Why?
| | Drug Discovery | 1 | 2013 | 131 | 0.490 |
Why?
| | Mucormycosis | 3 | 2005 | 21 | 0.480 |
Why?
| | Child, Preschool | 26 | 2022 | 9717 | 0.480 |
Why?
| | RNA, Viral | 12 | 2013 | 598 | 0.440 |
Why?
| | Meningococcal Vaccines | 2 | 2012 | 43 | 0.440 |
Why?
| | Female | 60 | 2022 | 63035 | 0.440 |
Why?
| | Cardiovirus Infections | 2 | 2000 | 3 | 0.440 |
Why?
| | Viral Vaccines | 2 | 2009 | 78 | 0.430 |
Why?
| | Male | 51 | 2022 | 60993 | 0.430 |
Why?
| | Oxazoles | 4 | 2015 | 36 | 0.410 |
Why?
| | Hepatitis B Vaccines | 1 | 2009 | 43 | 0.400 |
Why?
| | AIDS-Related Opportunistic Infections | 3 | 2015 | 122 | 0.390 |
Why?
| | Viral Load | 7 | 2017 | 470 | 0.390 |
Why?
| | Bacterial Vaccines | 1 | 2009 | 65 | 0.370 |
Why?
| | Fatigue Syndrome, Chronic | 1 | 2008 | 19 | 0.360 |
Why?
| | Pertussis Vaccine | 1 | 2007 | 21 | 0.360 |
Why?
| | Poliomyelitis | 2 | 1997 | 27 | 0.350 |
Why?
| | Communicable Diseases, Emerging | 1 | 2008 | 30 | 0.350 |
Why?
| | Mycetoma | 2 | 2004 | 5 | 0.340 |
Why?
| | Rhinitis | 3 | 2009 | 114 | 0.330 |
Why?
| | Viremia | 5 | 2021 | 127 | 0.330 |
Why?
| | Fetus | 3 | 2000 | 680 | 0.320 |
Why?
| | Immunoglobulins, Intravenous | 3 | 1997 | 150 | 0.310 |
Why?
| | Pregnancy | 16 | 2021 | 5290 | 0.300 |
Why?
| | Antibodies, Viral | 5 | 2022 | 526 | 0.290 |
Why?
| | Anti-Bacterial Agents | 3 | 2013 | 1331 | 0.290 |
Why?
| | Enterovirus B, Human | 3 | 2001 | 26 | 0.280 |
Why?
| | Anti-HIV Agents | 4 | 2017 | 681 | 0.280 |
Why?
| | Meningitis, Viral | 2 | 2004 | 24 | 0.280 |
Why?
| | Maxillary Sinusitis | 2 | 2004 | 8 | 0.280 |
Why?
| | Maus Elberfeld virus | 3 | 1993 | 5 | 0.270 |
Why?
| | Cytomegalovirus | 2 | 2016 | 144 | 0.260 |
Why?
| | Global Health | 2 | 2018 | 339 | 0.250 |
Why?
| | Acquired Immunodeficiency Syndrome | 2 | 2017 | 225 | 0.250 |
Why?
| | Placenta Diseases | 2 | 1995 | 13 | 0.250 |
Why?
| | Interferon-gamma | 2 | 2015 | 804 | 0.240 |
Why?
| | Centralized Hospital Services | 1 | 2001 | 5 | 0.240 |
Why?
| | Antifungal Agents | 3 | 2014 | 136 | 0.230 |
Why?
| | Oseltamivir | 2 | 2012 | 12 | 0.230 |
Why?
| | Fetal Diseases | 3 | 2000 | 192 | 0.230 |
Why?
| | Hepatitis, Viral, Human | 1 | 2001 | 28 | 0.230 |
Why?
| | United States | 13 | 2021 | 12329 | 0.220 |
Why?
| | Pneumonia, Viral | 2 | 2021 | 354 | 0.220 |
Why?
| | Retrospective Studies | 13 | 2021 | 11340 | 0.210 |
Why?
| | Research Support as Topic | 1 | 2001 | 125 | 0.210 |
Why?
| | Streptococcus pneumoniae | 3 | 2014 | 131 | 0.210 |
Why?
| | Colorado | 7 | 2021 | 4581 | 0.210 |
Why?
| | Ethmoid Sinusitis | 1 | 1999 | 2 | 0.210 |
Why?
| | Intracranial Hemorrhages | 1 | 2000 | 67 | 0.200 |
Why?
| | Hydrops Fetalis | 1 | 1999 | 16 | 0.200 |
Why?
| | Uterine Diseases | 1 | 1999 | 15 | 0.200 |
Why?
| | Neurodevelopmental Disorders | 1 | 2021 | 109 | 0.200 |
Why?
| | Drug Resistance, Microbial | 1 | 1999 | 68 | 0.200 |
Why?
| | Young Adult | 14 | 2017 | 10971 | 0.200 |
Why?
| | Embryonic Development | 1 | 2000 | 134 | 0.190 |
Why?
| | Polymerase Chain Reaction | 4 | 2016 | 1100 | 0.190 |
Why?
| | Mastoiditis | 2 | 2014 | 6 | 0.190 |
Why?
| | Enterovirus D, Human | 2 | 2018 | 65 | 0.190 |
Why?
| | Blood Coagulation Disorders | 1 | 2001 | 226 | 0.190 |
Why?
| | Fluoxetine | 1 | 2018 | 45 | 0.180 |
Why?
| | Heptavalent Pneumococcal Conjugate Vaccine | 2 | 2009 | 13 | 0.180 |
Why?
| | Nervous System Diseases | 2 | 2019 | 260 | 0.180 |
Why?
| | Arboviruses | 1 | 2017 | 10 | 0.180 |
Why?
| | Double-Blind Method | 3 | 2015 | 1673 | 0.180 |
Why?
| | Biliary Atresia | 1 | 2020 | 213 | 0.180 |
Why?
| | Nucleic Acid Hybridization | 6 | 1991 | 207 | 0.180 |
Why?
| | Allografts | 1 | 2018 | 106 | 0.170 |
Why?
| | Hospitals, Pediatric | 1 | 2001 | 500 | 0.170 |
Why?
| | HIV-1 | 2 | 2015 | 804 | 0.170 |
Why?
| | Disease Transmission, Infectious | 1 | 2018 | 61 | 0.170 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2013 | 909 | 0.170 |
Why?
| | Antibodies, Monoclonal | 2 | 2022 | 1302 | 0.170 |
Why?
| | Administration, Intravenous | 1 | 2018 | 145 | 0.170 |
Why?
| | In Situ Hybridization | 4 | 2000 | 342 | 0.170 |
Why?
| | Treatment Outcome | 9 | 2020 | 9002 | 0.170 |
Why?
| | Acyclovir | 2 | 2015 | 117 | 0.170 |
Why?
| | Endoscopy | 1 | 1999 | 238 | 0.170 |
Why?
| | Sexual Maturation | 1 | 2017 | 55 | 0.170 |
Why?
| | Immunization, Passive | 1 | 1997 | 79 | 0.170 |
Why?
| | Cytomegalovirus Retinitis | 1 | 2016 | 16 | 0.170 |
Why?
| | Postoperative Complications | 2 | 2016 | 2116 | 0.170 |
Why?
| | Clinical Trials as Topic | 1 | 2001 | 1009 | 0.160 |
Why?
| | Antibodies, Neutralizing | 2 | 2022 | 173 | 0.160 |
Why?
| | Practice Guidelines as Topic | 2 | 2022 | 1529 | 0.160 |
Why?
| | Respiratory Syncytial Virus Infections | 1 | 1997 | 90 | 0.160 |
Why?
| | Nasal Mucosa | 2 | 2009 | 93 | 0.160 |
Why?
| | Adoption | 1 | 2016 | 49 | 0.150 |
Why?
| | Brain | 3 | 2017 | 2686 | 0.150 |
Why?
| | Mice, Inbred ICR | 4 | 1997 | 118 | 0.150 |
Why?
| | Hyperlipidemias | 1 | 2017 | 146 | 0.150 |
Why?
| | Gastrointestinal Diseases | 1 | 2018 | 205 | 0.150 |
Why?
| | Congenital Abnormalities | 2 | 2010 | 68 | 0.150 |
Why?
| | Adult | 17 | 2022 | 31979 | 0.150 |
Why?
| | Follow-Up Studies | 7 | 2018 | 4906 | 0.150 |
Why?
| | Candidemia | 1 | 2015 | 6 | 0.150 |
Why?
| | Diagnosis, Differential | 2 | 2017 | 1432 | 0.150 |
Why?
| | Sexually Transmitted Diseases | 1 | 2017 | 165 | 0.150 |
Why?
| | DNA, Viral | 2 | 2016 | 442 | 0.150 |
Why?
| | Lymphocyte Subsets | 1 | 2015 | 88 | 0.150 |
Why?
| | Ganciclovir | 1 | 2015 | 48 | 0.150 |
Why?
| | Lymphopenia | 1 | 2015 | 57 | 0.150 |
Why?
| | Muscle Hypotonia | 1 | 2015 | 31 | 0.150 |
Why?
| | Oropharynx | 1 | 2015 | 40 | 0.140 |
Why?
| | Child Development | 2 | 2017 | 471 | 0.140 |
Why?
| | Cranial Nerve Diseases | 1 | 2015 | 45 | 0.140 |
Why?
| | Hearing Loss, Sensorineural | 1 | 2015 | 51 | 0.140 |
Why?
| | Chi-Square Distribution | 2 | 2013 | 572 | 0.140 |
Why?
| | Adenovirus Infections, Human | 2 | 1991 | 17 | 0.140 |
Why?
| | Incidence | 6 | 2017 | 2470 | 0.140 |
Why?
| | Risk Factors | 10 | 2021 | 9050 | 0.140 |
Why?
| | Liver Transplantation | 1 | 2020 | 718 | 0.140 |
Why?
| | Rectum | 1 | 2015 | 151 | 0.140 |
Why?
| | Controlled Clinical Trials as Topic | 1 | 2013 | 30 | 0.140 |
Why?
| | Beclomethasone | 1 | 1993 | 26 | 0.130 |
Why?
| | Puberty, Delayed | 1 | 2013 | 5 | 0.130 |
Why?
| | Mycoses | 1 | 2014 | 72 | 0.130 |
Why?
| | Antibody Affinity | 1 | 2013 | 56 | 0.130 |
Why?
| | Giant Cells | 1 | 1993 | 22 | 0.130 |
Why?
| | Hemagglutination Inhibition Tests | 1 | 2013 | 40 | 0.130 |
Why?
| | Candidiasis, Invasive | 1 | 2012 | 4 | 0.130 |
Why?
| | Cytomegalovirus Infections | 1 | 2015 | 188 | 0.130 |
Why?
| | Intensive Care Units, Pediatric | 1 | 2015 | 207 | 0.130 |
Why?
| | Candida | 1 | 2012 | 33 | 0.130 |
Why?
| | Orthomyxoviridae | 1 | 2012 | 28 | 0.130 |
Why?
| | Chickenpox | 1 | 1993 | 98 | 0.130 |
Why?
| | Viral Plaque Assay | 1 | 2012 | 26 | 0.120 |
Why?
| | Hospital Design and Construction | 1 | 1992 | 5 | 0.120 |
Why?
| | Neutralization Tests | 1 | 2012 | 72 | 0.120 |
Why?
| | Aircraft | 1 | 1992 | 27 | 0.120 |
Why?
| | Bacterial Infections | 2 | 2009 | 217 | 0.120 |
Why?
| | Ureaplasma urealyticum | 1 | 1991 | 3 | 0.120 |
Why?
| | Drug Resistance, Viral | 1 | 2012 | 103 | 0.120 |
Why?
| | Gestational Age | 4 | 2015 | 770 | 0.120 |
Why?
| | HIV | 1 | 2013 | 206 | 0.120 |
Why?
| | Chlamydia trachomatis | 1 | 1991 | 31 | 0.120 |
Why?
| | Chorioamnionitis | 1 | 1991 | 38 | 0.110 |
Why?
| | CD4-Positive T-Lymphocytes | 2 | 2017 | 1074 | 0.110 |
Why?
| | Severity of Illness Index | 4 | 2021 | 2828 | 0.110 |
Why?
| | Prospective Studies | 7 | 2017 | 6250 | 0.110 |
Why?
| | Trophoblasts | 1 | 1993 | 171 | 0.110 |
Why?
| | Decision Support Techniques | 1 | 2015 | 388 | 0.110 |
Why?
| | Peritoneovenous Shunt | 1 | 1990 | 1 | 0.110 |
Why?
| | Meningitis, Aseptic | 1 | 1990 | 14 | 0.110 |
Why?
| | Poliovirus Vaccine, Oral | 1 | 1990 | 19 | 0.110 |
Why?
| | Maternal-Fetal Exchange | 2 | 2007 | 168 | 0.110 |
Why?
| | Rimantadine | 1 | 2010 | 4 | 0.110 |
Why?
| | Cohort Studies | 5 | 2022 | 5011 | 0.110 |
Why?
| | Respiratory Tract Infections | 3 | 2016 | 267 | 0.110 |
Why?
| | Legionnaires' Disease | 1 | 1990 | 6 | 0.110 |
Why?
| | Biomarkers | 1 | 2021 | 3501 | 0.110 |
Why?
| | Adamantane | 1 | 2010 | 20 | 0.100 |
Why?
| | Poliovirus | 1 | 1990 | 79 | 0.100 |
Why?
| | Hepatitis B Antibodies | 1 | 2009 | 10 | 0.100 |
Why?
| | Cross Infection | 1 | 1992 | 204 | 0.100 |
Why?
| | Meningitis | 1 | 1990 | 68 | 0.100 |
Why?
| | Mice | 8 | 2000 | 15641 | 0.100 |
Why?
| | T-Lymphocytes | 2 | 2015 | 1846 | 0.100 |
Why?
| | Administration, Oral | 3 | 2012 | 798 | 0.090 |
Why?
| | South Africa | 1 | 2009 | 151 | 0.090 |
Why?
| | Maxillary Sinus | 2 | 2009 | 12 | 0.090 |
Why?
| | Mucor | 2 | 2005 | 8 | 0.090 |
Why?
| | Acute Kidney Injury | 1 | 2015 | 613 | 0.090 |
Why?
| | Age Factors | 4 | 2017 | 3330 | 0.090 |
Why?
| | Body Fluids | 1 | 1987 | 66 | 0.090 |
Why?
| | Drug Administration Schedule | 2 | 2015 | 825 | 0.080 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2022 | 634 | 0.080 |
Why?
| | Virus Diseases | 1 | 2009 | 181 | 0.080 |
Why?
| | Organ Transplantation | 1 | 2009 | 142 | 0.080 |
Why?
| | Evidence-Based Medicine | 3 | 2021 | 728 | 0.080 |
Why?
| | Aspergillosis | 2 | 2014 | 30 | 0.080 |
Why?
| | Reverse Transcriptase Inhibitors | 1 | 2007 | 83 | 0.080 |
Why?
| | Mitochondrial Diseases | 1 | 2007 | 68 | 0.080 |
Why?
| | Zygomycosis | 1 | 2006 | 6 | 0.080 |
Why?
| | Carotid Artery Thrombosis | 1 | 2005 | 6 | 0.080 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2004 | 1136 | 0.070 |
Why?
| | Statistics as Topic | 1 | 2006 | 365 | 0.070 |
Why?
| | Chronic Disease | 5 | 2009 | 1681 | 0.070 |
Why?
| | Drug Therapy, Combination | 2 | 2007 | 1004 | 0.070 |
Why?
| | Herpesvirus 7, Human | 1 | 2004 | 5 | 0.070 |
Why?
| | International Cooperation | 2 | 2018 | 183 | 0.070 |
Why?
| | Drug Resistance, Fungal | 1 | 2004 | 6 | 0.070 |
Why?
| | Scedosporium | 1 | 2004 | 2 | 0.070 |
Why?
| | Roseolovirus Infections | 1 | 2004 | 6 | 0.070 |
Why?
| | Longitudinal Studies | 3 | 2018 | 2692 | 0.070 |
Why?
| | Herpesvirus 6, Human | 1 | 2004 | 13 | 0.070 |
Why?
| | Respiratory Syncytial Viruses | 2 | 1997 | 47 | 0.070 |
Why?
| | Granulocyte Colony-Stimulating Factor | 1 | 2004 | 76 | 0.070 |
Why?
| | Animals | 9 | 2000 | 35394 | 0.070 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2004 | 164 | 0.070 |
Why?
| | Vaccines, Conjugate | 2 | 2014 | 52 | 0.060 |
Why?
| | Infant, Premature, Diseases | 2 | 1997 | 89 | 0.060 |
Why?
| | Biological Availability | 1 | 2003 | 159 | 0.060 |
Why?
| | Probability | 1 | 2003 | 341 | 0.060 |
Why?
| | Risk Assessment | 2 | 2020 | 3147 | 0.060 |
Why?
| | Growth Disorders | 1 | 2022 | 68 | 0.060 |
Why?
| | Bacteria, Aerobic | 1 | 2001 | 6 | 0.060 |
Why?
| | Drug Combinations | 1 | 2022 | 300 | 0.060 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2007 | 467 | 0.060 |
Why?
| | Disease Models, Animal | 3 | 2000 | 3910 | 0.060 |
Why?
| | Reference Values | 1 | 2003 | 877 | 0.060 |
Why?
| | Personnel Staffing and Scheduling | 1 | 2001 | 89 | 0.060 |
Why?
| | Income | 1 | 2022 | 165 | 0.060 |
Why?
| | Case-Control Studies | 3 | 2015 | 3369 | 0.050 |
Why?
| | Adenosine Monophosphate | 1 | 2021 | 51 | 0.050 |
Why?
| | Drug Approval | 1 | 2021 | 72 | 0.050 |
Why?
| | Alanine | 1 | 2021 | 104 | 0.050 |
Why?
| | RNA Probes | 2 | 1991 | 17 | 0.050 |
Why?
| | Disseminated Intravascular Coagulation | 1 | 2000 | 33 | 0.050 |
Why?
| | United States Food and Drug Administration | 1 | 2021 | 179 | 0.050 |
Why?
| | Systemic Inflammatory Response Syndrome | 1 | 2021 | 77 | 0.050 |
Why?
| | Picornaviridae Infections | 2 | 1990 | 27 | 0.050 |
Why?
| | Remission Induction | 1 | 2020 | 265 | 0.050 |
Why?
| | Amniotic Fluid | 2 | 1991 | 75 | 0.050 |
Why?
| | Necrosis | 1 | 2000 | 232 | 0.050 |
Why?
| | Fungi | 2 | 2014 | 119 | 0.050 |
Why?
| | Pharyngitis | 1 | 1999 | 23 | 0.050 |
Why?
| | Otitis Media with Effusion | 1 | 1999 | 21 | 0.050 |
Why?
| | Pseudallescheria | 1 | 1999 | 3 | 0.050 |
Why?
| | Cerebrospinal Fluid | 2 | 2004 | 95 | 0.050 |
Why?
| | Tissue and Organ Procurement | 1 | 2020 | 144 | 0.050 |
Why?
| | Opportunistic Infections | 1 | 1999 | 53 | 0.050 |
Why?
| | Zidovudine | 2 | 2010 | 80 | 0.050 |
Why?
| | Living Donors | 1 | 2020 | 202 | 0.050 |
Why?
| | Diabetes Mellitus, Type 1 | 2 | 2005 | 3307 | 0.050 |
Why?
| | Chlamydiaceae Infections | 1 | 2017 | 1 | 0.040 |
Why?
| | Epidemiological Monitoring | 1 | 2018 | 48 | 0.040 |
Why?
| | Nutrition Disorders | 1 | 1997 | 26 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2003 | 2229 | 0.040 |
Why?
| | Otitis Media | 1 | 1999 | 126 | 0.040 |
Why?
| | Spinal Cord | 1 | 2000 | 406 | 0.040 |
Why?
| | Time Factors | 1 | 2009 | 7060 | 0.040 |
Why?
| | Abortion, Spontaneous | 1 | 1997 | 76 | 0.040 |
Why?
| | Internationality | 1 | 2018 | 150 | 0.040 |
Why?
| | Reoperation | 1 | 1999 | 538 | 0.040 |
Why?
| | Ophthalmoscopy | 1 | 2016 | 25 | 0.040 |
Why?
| | Sex Factors | 2 | 2017 | 1997 | 0.040 |
Why?
| | Antigens, Viral | 1 | 2017 | 184 | 0.040 |
Why?
| | B-Lymphocytes | 2 | 2015 | 832 | 0.040 |
Why?
| | Encephalomyelitis | 1 | 2016 | 7 | 0.040 |
Why?
| | Plasma Cells | 2 | 2009 | 63 | 0.040 |
Why?
| | Multicenter Studies as Topic | 1 | 1997 | 222 | 0.040 |
Why?
| | Acute Disease | 1 | 1999 | 1000 | 0.040 |
Why?
| | Heart | 1 | 2000 | 685 | 0.040 |
Why?
| | Enzyme-Linked Immunospot Assay | 1 | 2015 | 42 | 0.040 |
Why?
| | Immune Tolerance | 2 | 1999 | 362 | 0.040 |
Why?
| | Malnutrition | 1 | 2016 | 55 | 0.040 |
Why?
| | AIDS Dementia Complex | 1 | 2015 | 55 | 0.040 |
Why?
| | Caribbean Region | 1 | 2015 | 24 | 0.040 |
Why?
| | Hematologic Neoplasms | 1 | 2016 | 121 | 0.040 |
Why?
| | North America | 1 | 2016 | 274 | 0.040 |
Why?
| | Coinfection | 1 | 2016 | 109 | 0.040 |
Why?
| | Molecular Diagnostic Techniques | 1 | 2016 | 95 | 0.040 |
Why?
| | Encephalitis, Varicella Zoster | 1 | 2015 | 20 | 0.040 |
Why?
| | Encephalitis, Herpes Simplex | 1 | 2015 | 21 | 0.040 |
Why?
| | Audiometry | 1 | 2015 | 33 | 0.040 |
Why?
| | Latin America | 1 | 2015 | 70 | 0.040 |
Why?
| | Transplantation, Homologous | 1 | 2016 | 490 | 0.040 |
Why?
| | Evaluation Studies as Topic | 1 | 1995 | 226 | 0.040 |
Why?
| | Papillomavirus Infections | 1 | 2017 | 222 | 0.040 |
Why?
| | Papillomavirus Vaccines | 1 | 2017 | 189 | 0.040 |
Why?
| | Patient Outcome Assessment | 1 | 2016 | 124 | 0.040 |
Why?
| | Biopsy | 3 | 2009 | 1065 | 0.040 |
Why?
| | Physical Conditioning, Animal | 1 | 1997 | 232 | 0.040 |
Why?
| | Neutropenia | 1 | 2015 | 133 | 0.040 |
Why?
| | Canada | 1 | 2015 | 336 | 0.040 |
Why?
| | C-Reactive Protein | 1 | 2017 | 363 | 0.030 |
Why?
| | Microscopy, Electron | 1 | 1995 | 464 | 0.030 |
Why?
| | Evoked Potentials, Auditory, Brain Stem | 1 | 2015 | 51 | 0.030 |
Why?
| | Odds Ratio | 1 | 2017 | 1064 | 0.030 |
Why?
| | Metabolic Diseases | 1 | 2015 | 112 | 0.030 |
Why?
| | Infusions, Intravenous | 1 | 2015 | 412 | 0.030 |
Why?
| | Pandemics | 1 | 2021 | 881 | 0.030 |
Why?
| | Combined Modality Therapy | 3 | 2005 | 1243 | 0.030 |
Why?
| | Administration, Intranasal | 1 | 1993 | 89 | 0.030 |
Why?
| | Infant, Premature | 1 | 1997 | 449 | 0.030 |
Why?
| | Mortality | 1 | 2015 | 328 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2017 | 1599 | 0.030 |
Why?
| | Electromyography | 1 | 2015 | 330 | 0.030 |
Why?
| | Epidemiologic Studies | 1 | 2012 | 59 | 0.030 |
Why?
| | Sexual Behavior | 1 | 2017 | 450 | 0.030 |
Why?
| | Sequence Analysis, DNA | 1 | 2016 | 798 | 0.030 |
Why?
| | Prognosis | 1 | 2001 | 3544 | 0.030 |
Why?
| | Tomography, X-Ray Computed | 2 | 1999 | 2380 | 0.030 |
Why?
| | Neisseria meningitidis | 1 | 2012 | 18 | 0.030 |
Why?
| | Oncology Service, Hospital | 1 | 1992 | 16 | 0.030 |
Why?
| | Meningococcal Infections | 1 | 2012 | 22 | 0.030 |
Why?
| | Ventilation | 1 | 1992 | 31 | 0.030 |
Why?
| | Ureaplasma Infections | 1 | 1991 | 3 | 0.030 |
Why?
| | Mycoplasma Infections | 1 | 1991 | 15 | 0.030 |
Why?
| | Amniocentesis | 1 | 1991 | 26 | 0.030 |
Why?
| | T-Lymphocyte Subsets | 1 | 2015 | 450 | 0.030 |
Why?
| | Europe | 1 | 2012 | 351 | 0.030 |
Why?
| | Microbial Viability | 1 | 2012 | 76 | 0.030 |
Why?
| | Logistic Models | 1 | 2017 | 2053 | 0.030 |
Why?
| | Adenoviruses, Human | 1 | 1991 | 28 | 0.030 |
Why?
| | Chlamydia Infections | 1 | 1991 | 57 | 0.030 |
Why?
| | Flow Cytometry | 1 | 2015 | 1184 | 0.030 |
Why?
| | Respirovirus Infections | 1 | 1990 | 13 | 0.030 |
Why?
| | Paramyxoviridae Infections | 1 | 1990 | 14 | 0.030 |
Why?
| | Hospitals, University | 1 | 1991 | 194 | 0.030 |
Why?
| | Rhinovirus | 1 | 1990 | 37 | 0.030 |
Why?
| | Anti-Infective Agents | 1 | 2013 | 234 | 0.030 |
Why?
| | Inpatients | 1 | 2014 | 335 | 0.030 |
Why?
| | Comorbidity | 1 | 2016 | 1601 | 0.030 |
Why?
| | Benzoxazines | 1 | 2010 | 28 | 0.030 |
Why?
| | Cyclopropanes | 1 | 2010 | 79 | 0.030 |
Why?
| | Lymphocyte Activation | 1 | 2015 | 1165 | 0.030 |
Why?
| | Legionella | 1 | 1990 | 7 | 0.030 |
Why?
| | Alkynes | 1 | 2010 | 56 | 0.030 |
Why?
| | Leukemia | 1 | 1992 | 214 | 0.030 |
Why?
| | Immunohistochemistry | 1 | 1995 | 1831 | 0.030 |
Why?
| | Population Surveillance | 1 | 1993 | 439 | 0.030 |
Why?
| | Hospitals | 1 | 2014 | 468 | 0.030 |
Why?
| | Dermatomyositis | 1 | 1989 | 23 | 0.030 |
Why?
| | Sensitivity and Specificity | 1 | 1995 | 1930 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 2 | 2015 | 3049 | 0.020 |
Why?
| | Cells, Cultured | 1 | 1997 | 4429 | 0.020 |
Why?
| | Peroxidase | 1 | 2009 | 207 | 0.020 |
Why?
| | Natural Killer T-Cells | 1 | 2009 | 57 | 0.020 |
Why?
| | Staining and Labeling | 1 | 2009 | 171 | 0.020 |
Why?
| | Muscles | 1 | 1989 | 331 | 0.020 |
Why?
| | Seasons | 1 | 1990 | 439 | 0.020 |
Why?
| | Respiratory Tract Diseases | 1 | 1990 | 158 | 0.020 |
Why?
| | Picornaviridae | 1 | 1988 | 18 | 0.020 |
Why?
| | Ribonucleases | 1 | 1987 | 57 | 0.020 |
Why?
| | Central Nervous System | 1 | 2010 | 248 | 0.020 |
Why?
| | HIV Reverse Transcriptase | 1 | 2007 | 30 | 0.020 |
Why?
| | Lamivudine | 1 | 2007 | 56 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2016 | 4275 | 0.020 |
Why?
| | Cavernous Sinus | 1 | 2005 | 13 | 0.020 |
Why?
| | Telencephalon | 1 | 2005 | 19 | 0.020 |
Why?
| | Antigens, CD | 1 | 2009 | 508 | 0.020 |
Why?
| | Infectious Disease Transmission, Vertical | 1 | 2007 | 133 | 0.020 |
Why?
| | Orbit | 1 | 2005 | 42 | 0.020 |
Why?
| | Paranasal Sinuses | 1 | 2005 | 58 | 0.020 |
Why?
| | Exocrine Glands | 1 | 2004 | 5 | 0.020 |
Why?
| | Basement Membrane | 1 | 2004 | 34 | 0.020 |
Why?
| | Prevalence | 1 | 2010 | 2407 | 0.020 |
Why?
| | Cell Count | 1 | 2004 | 334 | 0.020 |
Why?
| | RNA | 1 | 1988 | 776 | 0.020 |
Why?
| | Neutrophils | 1 | 2009 | 1324 | 0.020 |
Why?
| | Lymphocytes | 1 | 2004 | 392 | 0.010 |
Why?
| | Eosinophils | 1 | 2004 | 269 | 0.010 |
Why?
| | Penicillin Resistance | 1 | 2001 | 8 | 0.010 |
Why?
| | Macrophages | 1 | 2009 | 1343 | 0.010 |
Why?
| | beta-Lactamases | 1 | 2001 | 21 | 0.010 |
Why?
| | Haemophilus influenzae | 1 | 2001 | 49 | 0.010 |
Why?
| | Staphylococcus | 1 | 2001 | 71 | 0.010 |
Why?
| | Drug Resistance, Multiple, Bacterial | 1 | 2001 | 64 | 0.010 |
Why?
| | Drug Resistance, Bacterial | 1 | 2001 | 153 | 0.010 |
Why?
| | Nasal Decongestants | 1 | 1999 | 9 | 0.010 |
Why?
| | Otorhinolaryngologic Surgical Procedures | 1 | 1999 | 37 | 0.010 |
Why?
| | Steroids | 1 | 1999 | 136 | 0.010 |
Why?
| | Recurrence | 1 | 1999 | 967 | 0.010 |
Why?
| | Anti-Inflammatory Agents | 1 | 1999 | 460 | 0.010 |
Why?
| | Patient Selection | 1 | 1999 | 694 | 0.010 |
Why?
| | RNA, Antisense | 1 | 1988 | 24 | 0.010 |
Why?
| | DNA, Recombinant | 1 | 1988 | 47 | 0.010 |
Why?
| | Sequence Homology, Nucleic Acid | 1 | 1988 | 170 | 0.010 |
Why?
| | Aged | 1 | 2006 | 20109 | 0.010 |
Why?
| | Virus Replication | 1 | 1988 | 434 | 0.000 |
Why?
| | Middle Aged | 1 | 2006 | 28753 | 0.000 |
Why?
| | Cell Line | 1 | 1988 | 3016 | 0.000 |
Why?
| | DNA | 1 | 1988 | 1417 | 0.000 |
Why?
|
|
Abzug's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|